Supplementary Online Content

Peljto AL, Zhang Y, Fingerlin TE, et al. Association between the *MUC5B* promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. *JAMA*. doi:10.1001/jama.2013.5827

eFigure 1. Flow Diagram of Patients Included in Each Cohort

eTable 1. Survival Analysis Model in INSPIRE Cohort, Adjusted for MMP-7 and Treatment

eTable 2. Survival Analysis Model in INSPIRE Cohort, Adjusted for MMP-7, Treatment, and Interaction

This supplementary material has been provided by the authors to give readers additional information about their work.

eFigure 1. Flow Diagram of Patients Included in Each Cohort

471 enrolled IPF Patients	
	33 excluded
	4 missing genetic data
	29 not non-Hispanic white
438 included in analysis	

INSPIRE

157 enrolled IPF Patients	
	9 excluded
	(missing genetic data)
148 included in analysis	

Chicago

eTable 1. Survival Analysis Model in INSPIRE Cohort, Adjusted for MMP-7 and Treatment

Variable[a]	HR (95% CI)	p-value
MMP7 (<5.7ng/ml)	2.18 (1.10 – 4.32)	0.03
MUC5B		<0.001
GT	0.44 (0.29 – 0.68)	
TT	0.20 (0.08 – 0.47	
FVC (liters)	0.55 (0.34 – 0.89)	0.01
DLCO (ml/min/mm Hg)	0.89 (0.85 – 0.95)	<0.001
Sex (male)	0.25 (0.12 – 0.53)	<0.001
Treatment (placebo)	1.48 (0.86 – 2.51)	0.16

[a]Reference group and units shown in parentheses for categorical and continuous predictors, respectively.

eTable 2. Survival Analysis Model in INSPIRE Cohort, Adjusted for MMP-7, Treatment, and Interaction

Variable[a]	HR[b] (95% CI)	p-value
MMP7 (<5.7ng/ml)	2.32 (0.30 – 0.71)	0.02
MUC5B	--	0.63
FVC (liters)	0.54 (0.33 – 0.87)	0.01
DLCO (ml/min/mm Hg)	0.89 (0.84 – 0.94)	<0.001
Sex (male)	0.23 (0.11 – 0.50)	<0.001
Treatment (placebo)	--	0.03
Treatment*MUC5B	--	0.07

[a]Reference group and units shown in parentheses for categorical and continuous predictors, respectively.
[b]Hazard ratios not available for covariates involved in interaction terms.